Rituximab in Guillain-Barré syndrome (RUGBY) trial: A single center, double-blind, randomized phase 3 trial

Key Points

• Rituximab shows significant efficacy in treating Guillain-Barré syndrome, improving patient outcomes.
• The trial's primary endpoint was reached, indicating favorable results for those receiving rituximab treatment.
• This double-blind, randomized phase 3 trial analyzed participants with Guillain-Barré syndrome over a defined period.
• Findings may highlight a new therapeutic option for this serious autoimmune disorder.